ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2009
Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Erythropoietin (EPO) for Neuroprotection in Human Studies.Neurochemical research · 2021Pooled it
- Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients.International journal of molecular sciences · 2016Trial
- Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.BMJ open · 2016Trial
- Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Trial
- Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial.Stem cells (Dayton, Ohio) · 2013Trial
- Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia--a dose-response trial.Cerebellum (London, England) · 2011Trial
- Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia.Molecular psychiatry · 2011Trial
- Intramuscular delivery of recombinant AAV expressing EpoR76E improves memory and is neuroprotective in 5xFAD transgenics.Research square · 2025Article
- Carbamoylated Erythropoietin Rescues Autism-Relevant Social Deficits in BALB/cJ Mice.NeuroSci · 2025Article
- Review
- Epoetin alfa has a potent anxiolytic effect on naive female rats.BMC pharmacology & toxicology · 2025Article
- EPO Deficiency Upregulates GADD45b/p38 MAPK Axis, Mediating Schizophrenia-Related Synaptic and Cognitive Impairments.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Erythropoietin restrains the inhibitory potential of interneurons in the mouse hippocampus.Molecular psychiatry · 2024Article
- Chemogenetic inhibition of amygdala excitatory neurons impairs rhEPO-enhanced contextual fear memory after TBI.Neuroscience letters · 2023Article
- Peripheral Nerve Regeneration: Opportunities and Challenges.Journal of spine research and surgery · 2023Article
- Introducing the brain erythropoietin circle to explain adaptive brain hardware upgrade and improved performance.Molecular psychiatry · 2022Review
- Erythropoietin as a Neuroprotective Drug for Newborn Infants: Ten Years after the First Use.Antioxidants (Basel, Switzerland) · 2022Review
- Addressing the 'hypoxia paradox' in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues.Molecular medicine (Cambridge, Mass.) · 2021Review
- Regulation of inflammatory cytokines for spinal cord injury recovery.Histology and histopathology · 2021Review
- Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy.Alzheimer's research & therapy · 2021Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growth factor erythropoietin (EPO) and erythropoietin receptors (EPOR) are expressed in the nervous system. Neuronal expression of EPO and EPOR peaks during brain development and is upregulated in the adult brain after injury. Peripherally administered EPO, and at least some of its variants, cross the blood-brain barrier, stimulate neurogenesis, neuronal differentiation, and activate brain neurotrophic, anti-apoptotic, anti-oxidant and anti-inflammatory signaling. These mechanisms underlie their tissue protective effects in nervous system disorders. As the tissue protective functions of EPO can be separated from its stimulatory action on hematopoiesis, novel EPO derivatives and mimetics, such as asialo-EPO and carbamoylated EPO have been developed. While the therapeutic potential of the novel EPO derivatives continues to be characterized in preclinical studies, the experimental findings in support for the use of recombinant human (rh)EPO in human brain disease have already been translated to clinical studies in acute ischemic stroke, chronic schizophrenia, and chronic progressive multiple sclerosis. In this review article, we assess the studies on EPO and, in particular, on its structural or functional variants in experimental models of nervous system disorders, and we provide a short overview of the completed and ongoing clinical studies testing EPO as neuroprotective/neuroregenerative treatment option in neuropsychiatric disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.